USV enters Germany by snapping up Juta
Executive Summary
Privately-owned Indian company USV is entering “the highly competitive German drug market” by acquiring local generics player Juta Pharma for an undisclosed fee. The German firm – which has “more than 50 marketing authorisations for generic drugs” – was part of Watson’s Arrow Group until a management buy-out in 2013.
You may also be interested in...
India's USV Reveals Investment Plans
Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its existing API unit near Mumbai as it eyes expanded capacity and additional sales in Europe.
USV’s Juta Gets An EU Pegfilgrastim Nod
Juta Pharma has received a positive opinion from the European Medicines Agency’s CHMP recommending granting a pan-European marketing authorization for its biosimilar pegfilgrastim, Grasustek.
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.